Lassane Kabore1, Paul Muntner1, Eric Chamot1, Anne Zinski2, Greer Burkholder2, Michael J Mugavero3. 1. Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA. 2. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA. 3. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA mmugavero@uab.edu.
Abstract
BACKGROUND: Adherence is a major determinant of the effectiveness of antiretroviral therapy (ART). We determined the association between self-reported adherence (SRA) and medication possession ratio (MPR), a pharmacy-based adherence measure, and their respective associations with viral load. METHODS: Adherence to ART was assessed by MPR over 6 months and by self-report which included a question with a Likert-type scale response, a visual analogue scale (VAS), and an inquiry about the last time the patients skipped any prescribed medications. RESULTS: Taking MPR as the "gold standard," all 3 SRA measures displayed high specificity but low sensitivity. The prevalence ratio (95% confidence interval) for viral load ≥50 copies/mL was 2.19 (1.07-4.50) for MPR <90%, 1.98 (1.04-3.78) for poor/fair/good versus excellent/very good ability to take antiretroviral drugs, 1.47 (0.79-2.75) for skipping medications within the past 2 weeks, and 2.51 (1.39-4.53) for VAS <95%. CONCLUSION: These data suggest various SRA measures hold clinical value in screening for poor ART adherence.
BACKGROUND: Adherence is a major determinant of the effectiveness of antiretroviral therapy (ART). We determined the association between self-reported adherence (SRA) and medication possession ratio (MPR), a pharmacy-based adherence measure, and their respective associations with viral load. METHODS: Adherence to ART was assessed by MPR over 6 months and by self-report which included a question with a Likert-type scale response, a visual analogue scale (VAS), and an inquiry about the last time the patients skipped any prescribed medications. RESULTS: Taking MPR as the "gold standard," all 3 SRA measures displayed high specificity but low sensitivity. The prevalence ratio (95% confidence interval) for viral load ≥50 copies/mL was 2.19 (1.07-4.50) for MPR <90%, 1.98 (1.04-3.78) for poor/fair/good versus excellent/very good ability to take antiretroviral drugs, 1.47 (0.79-2.75) for skipping medications within the past 2 weeks, and 2.51 (1.39-4.53) for VAS <95%. CONCLUSION: These data suggest various SRA measures hold clinical value in screening for poor ART adherence.
Authors: Maryam M Asgari; G Thomas Ray; Charles P Quesenberry; Kenneth A Katz; Michael J Silverberg Journal: JAMA Dermatol Date: 2017-09-01 Impact factor: 10.282
Authors: Sarah Wood; Robert Gross; Judy A Shea; José A Bauermeister; Joshua Franklin; Danielle Petsis; Meghan Swyryn; Linden Lalley-Chareczko; Helen C Koenig; Nadia Dowshen Journal: AIDS Behav Date: 2019-10
Authors: Mira Wang; Joshua D Miller; Shalean M Collins; Marianne V Santoso; Pauline Wekesa; Hideaki Okochi; Maricianah Onono; Sheri Weiser; Monica Gandhi; Sera L Young Journal: AIDS Behav Date: 2020-10
Authors: Sarah M Lofgren; Melanie R Nicol; Tadeo K Kandole; Jose Castillo-Mancilla; Peter L Anderson; Edward Mpoza; Lillian Tugume; Ananta S Bangdiwala; Kenneth Ssebambulidde; Katherine Huppler Hullsiek; Joshua Rhein; David B Meya; David R Boulware Journal: AIDS Res Hum Retroviruses Date: 2021-04-12 Impact factor: 1.723
Authors: Satyanand Satyanarayana; Brooke G Rogers; Sierra A Bainter; Katerina A Christopoulos; Rob J Fredericksen; William C Mathews; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Adam W Carrico; Matthew J Mimiaga; Kenneth H Mayer; Heidi M Crane; Steven A Safren Journal: AIDS Patient Care STDS Date: 2021-06 Impact factor: 5.944